US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Genmab A/S

< Previous 1 2 3 4 Next >
News headline image
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Financial Results for the First Half of 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Financial Results for the First Quarter of 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Publishes 2025 Annual Report
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Portfolio Prioritization Update
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Portfolio Prioritization Update
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
From Genmab A/S
Via Business Wire
Tickers GMAB MRUS
News headline image
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
From Genmab A/S
Via GlobeNewswire
< Previous 1 2 3 4 Next >